|
Market Cap (5-Jun) $61,568,592 (1,444th) |
Close (30-Jun) $0.076 |
Volume (30-Jun) 120,981 |
Shortsold (26-May) 11,577 (0.00%) (629th) |
|
52w High $0.425 |
52w Low $0.056 |
P/E - |
EPS -0.02 |
ATX released this announcement to the ASX on 24 November 2021, 16:45. The announcement is marked as price sensitive, and is 22 page(s) in length and 868kb in size.
You can view all announcements from ATX and see how they appear on a price chart on the announcements page.
At the date of this announcement, ATX was 0.033% short sold according to ASIC data. It was ranked the 549th most shorted stock on the ASX. It remains ranked 629th as of the latest reported data (26 May 2026).
| Other Recent Announcements from ATX | |
|---|---|
| AMP945 International Nonproprietary Name Narmafotinib | 21 June 2023, 8:34 |
| Amplia AGM to be held Thursday 24 August 2023 | 19 June 2023, 17:34 |
| Key to Corporate Governance Disclosures | 31 May 2023, 8:14 |
| App 4D and Financial Report Half Year ended 30 Sep 2021 | 24 November 2021, 16:45 |
| Notice of Extraordinary General Meeting - 17 Dec 2021 | 19 November 2021, 10:21 |
| Summary Results - Successful Phase 1 Clinical Trial AMP945 | 18 November 2021, 8:54 |
| Inhibition of FAK by AMP945 in Phase 1 Clinical Trial | 17 November 2021, 8:25 |
You must be logged in to post a reply.
Amplia Therapeutics 